Media Coverage

Patients across the U.S. will soon have access to a new cervical cancer test collected from the comfort of their own home—no stirrups, speculum, or in-person doctor’s visit needed. The life sciences company Waters is partnering with Quest Diagnostics to make Waters’ Onclarity HPV Self-Collection Kit available for use at home. The partnership, announced Tuesday, will begin making self-collection kits available in early 2027.

We’re taking a closer look at new research highlighting the risks of tick-borne diseases. A study by Quest Diagnostics, published in JAMA Network Open, found that nearly one in three patients with antibodies for Lyme disease also had antibodies for at least one other tick-borne pathogen. Joining us to break down the findings and explain what they mean for diagnosis and treatment is Dr. Emily Schindler, Medical Director of Infectious Disease and Immunology at Quest Diagnostics.

Quest Diagnostics calls for passage of RESULTS Act as survey shows 96% of voters value lab testing. Claire Wallace,Senior Writer,Informa Markets – Engineering Quest Diagnostics is calling on Congress to pass the RESULTS Act before scheduled Medicare laboratory payment cuts take effect in January 2027, citing new survey data showing overwhelming public support for protecting access to diagnostic testing and concerns about the flawed rate-setting process under current law.

The ctDNA liquid biopsy demonstrated 100% specificity and outperformed standard CEA testing in residual specimen analysis. A study published in The Journal of Molecular Diagnostics shows that the Haystack MRD test accurately detects residual and recurrent colorectal cancer, demonstrating clinical performance in patient specimens from the DYNAMIC clinical trial series. The study also validated the test’s analytical performance across 23 solid tumor types.

Despite the surge of people who embraced healthier lifestyles amid the new perspectives they’d gained during the pandemic, drug use still remains significant among U.S. workers. Recent data analysis by testing company Quest Diagnostics found that nearly 20 percent of employees generated positive results for a range of illicit substances in 2025, “potentially reflecting recurring or chronic drug use.”

A positive Lyme disease antibody result may signal a need to consider other tick-borne pathogens, according to a study of 193,260 individuals tested at Quest Diagnostics. In the U.S. Northeast, 31.1% of people positive for B. burgdorferi also tested positive for at least one of those other three pathogens, Yonghong Li, PhD, of Quest Diagnostics in San Juan Capistrano, California, and colleagues reported in a JAMA Network Open research letter.

With CMS poised to release clinical lab payment rates with statutorily mandated reductions of up to 15%, Quest Diagnostics is highlighting a survey finding that consumers across party lines view lab tests as critical to their care and is urging Congress to pass the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act before the cuts kick in on Jan. 1.

With the US Food and Drug Administration (FDA) recently clearing two blood-based Alzheimer’s tests and additional regulatory clearances expected in the near future, the market for such assays is an increasingly crowded one. he clinical laboratory firms Quest Diagnostics and Laboratory Corporation of America offer both the FDA-cleared Roche and Fujirebio tests and their own laboratory-developed Alzheimer’s blood tests. “There is a little bit of difference in the performance of the tests,” said Michael Racke, medical director for neurology at Quest. He noted, for instance, that studies have indicated mass spectrometry (used by C2N in PrecivityAD2) may offer better measurement of plasma Aβ 40/42 than immunoassays, a finding that he said influenced Quest’s decision to use mass spec for its AD-Detect Alzheimer’s LDT. Different immunoassays have also shown differences in performance, he said.

Labcorp and Quest Diagnostics see solid growth on the horizon for laboratory companies as health systems try to blunt financial headwinds and patients seek more on-demand services. After acquiring lab assets from systems such as Minneapolis-based Allina Health, Columbus, Ohio-based OhioHealth, Franklin, Tennessee-based Community Health Systems and Fort Wayne, Indiana-based Parkview Health, the two dominant national commercial laboratory companies have set their focus on broadening test menus and direct-to-patient offerings.

Quest Diagnostics announced that Apple Health app users across most of the United States will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. The Quest laboratory panel is designed to deliver preventive health insights and includes biomarkers for assessing cardiometabolic health and organ function.